Evidence map›Paper›PMID 12052898›Full record

ArticleMolecular and cellular biology2002

Maleylacetoacetate isomerase (MAAI/GSTZ)-deficient mice reveal a glutathione-dependent nonenzymatic bypass in tyrosine catabolism.

José Manuel Fernández-Cañón, Manfred W Baetscher, Milton Finegold, Terry Burlingame, K Michael Gibson, Markus Grompe

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00865514 (Pharmacotoxicology of Trichloroethylene Metabolites), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00865514 naterminatednot on this mapstarted 2011, after this paper: background citation

Pharmacotoxicology of Trichloroethylene Metabolites: Short-term Effect of DCA on in Vivo Tyrosine Catabolism and MAAI Expression

TypeinterventionalSponsorUniversity of FloridaRan2011 to 2012Enrolled2ConditionsHealthyArmsDichloroacetate, Genotyping, Leucine, tyrosine
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

José Manuel Fernández-CañónDepartment of Molecular and Medical Genetics, Oregon Health Sciences University, Portland, Oregon, USA. dbbfjc@unileon.es
Manfred W Baetscher
Milton Finegold
Terry Burlingame
K Michael Gibson
Markus Grompe
Oregon Health & Science University · USTexas Children's Hospital · US

Funding

Treatment of Distal Tyrosine Pathway DisordersR01DK048252 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI GROMPE, MARKUS · 1994 to 2017
$5.5M
NIDDK NIH HHS R01 DK048252NIDDK NIH HHS R01-DK48252
6 · The paper itself

Abstract

In mammals, the catabolic pathway of phenylalanine and tyrosine is found in liver (hepatocytes) and kidney (proximal tubular cells). There are well-described human diseases associated with deficiencies of all enzymes in this pathway except for maleylacetoacetate isomerase (MAAI), which converts maleylacetoacetate (MAA) to fumarylacetoacetate (FAA). MAAI is also known as glutathione transferase zeta (GSTZ1). Here, we describe the phenotype of mice with a targeted deletion of the MAAI (GSTZ1) gene. MAAI-deficient mice accumulated FAA and succinylacetone in urine but appeared otherwise healthy. This observation suggested that either accumulating MAA is not toxic or an alternate pathway for MAA metabolism exists. A complete redundancy of MAAI could be ruled out because substrate overload of the tyrosine catabolic pathway (administration of homogentisic acid, phenylalanine, or tyrosine) resulted in renal and hepatic damage. However, evidence for a partial bypass of MAAI activity was also found. Mice doubly mutant for MAAI and fumarylacetoacetate hydrolase (FAH) died rapidly on a normal diet, indicating that MAA could be isomerized to FAA in the absence of MAAI. Double mutants showed predominant renal injury, indicating that this organ is the primary target for the accumulated compound(s) resulting from MAAI deficiency. A glutathione-mediated isomerization of MAA to FAA independent of MAAI enzyme was demonstrated in vitro. This nonenzymatic bypass is likely responsible for the lack of a phenotype in nonstressed MAAI mutant mice.

Indexed as

AcetoacetatesAnimalscis-trans-IsomerasesDietFemaleGlutathioneHomogentisic AcidMaleMiceMice, KnockoutMice, Mutant StrainsTyrosineAcetoacetatescis-trans-IsomerasesfumarylacetoacetateGlutathioneHomogentisic Acidmaleylacetoacetate isomeraseTyrosine

Identifiers

PMID12052898
PMCPMC133921
OpenAlexW2161824310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.